Novoplansky, O., Shnerb, A. B., Marripati, D., Jagadeeshan, S., Shareb, R. A., Conde‐López, C., . . . Elkabets, M. (2023). Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer. Wiley.
Chicago Style (17th ed.) CitationNovoplansky, Ofra, et al. Activation of the EGFR/PI3K/AKT Pathway Limits the Efficacy of Trametinib Treatment in Head and Neck Cancer. Wiley, 2023.
MLA (9th ed.) CitationNovoplansky, Ofra, et al. Activation of the EGFR/PI3K/AKT Pathway Limits the Efficacy of Trametinib Treatment in Head and Neck Cancer. Wiley, 2023.
Warning: These citations may not always be 100% accurate.